trial

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCTId NCT00690274
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 52 (actual)
Sponsored by University of Texas Southwestern Medical Center
Primary completion 2011-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
52 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-06
Primary completion
2011-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
BF2.649

Sponsors

University of Texas Southwestern Medical CenterLead Sponsor
BioprojetCollaborator
Stanley Medical Research InstituteCollaborator

Investigators

1
Carol A Tamminga, MDPrincipal Investigator

Sites

2 total
Dallas, United StatesDallas, United States

Linked catalysts

1
Study to Demonstrate Cognitive Enhancing Effects of BF2.649 — primary completion2011-10

Facts & assertions

4 sourced
Enrollment
52
Phase
PHASE2
Primary Completion Date
2011-10
Status
COMPLETED
relationships
The graph out of here
drug
BF2.649
drug
lead_sponsor
University of Texas Southwestern Medical Center
company
collaborator
Bioprojet
company
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Carol A Tamminga, MD
person